The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
Author:
Publisher
Springer Science and Business Media LLC
Subject
Ophthalmology,General Medicine
Link
http://link.springer.com/article/10.1186/1471-2415-12-46/fulltext.html
Reference64 articles.
1. Mohamed Q, Gillies MC, Wong TY: Management of diabetic retinopathy: a systematic review. J Am Med Assoc. 2007, 298: 902-916. 10.1001/jama.298.8.902.
2. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG: FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007, 370: 1687-1697. 10.1016/S0140-6736(07)61607-9.
3. ACCORD Study Group and ACCORD Eye Study: Effects of medical therapies on retinopathy progression in Type 2 Diabetes. N Engl J Med. 2010, 363: 233-244.
4. Shen LQ, Child A, Weber GM, Folkman J, Aiello LP: Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy. Arch Ophthalmol. 2008, 126: 793-799. 10.1001/archopht.126.6.793.
5. Kota BP, Huang THW, Roufogalis BD: An overview on biological mechanisms of PPARs. Pharmacol Res. 2005, 51: 85-94. 10.1016/j.phrs.2004.07.012.
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Diabetes mellitus associated neurovascular lesions in the retina and brain: A review;Frontiers in Ophthalmology;2022-10-31
2. Proteomics of Vitreous Humor Reveals PPARA, RXR, and LXR Are Possible Upstream Regulators of Proliferative Diabetic Retinopathy;Frontiers in Medicine;2021-08-17
3. Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases;International Journal of Molecular Sciences;2020-12-04
4. Retinal and circulating miRNAexpression patterns in diabetic retinopathy: An in silico and in vivo approach;British Journal of Pharmacology;2019-05-09
5. Peroxisome Proliferated Activated Receptors (PPARs): Opportunities and Challenges for Ocular Therapy;Critical Reviews™ in Therapeutic Drug Carrier Systems;2018
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3